How much does a box of the latest cimepilimab cost in 2024?

A drug that binds to the proteinPD-1 to help immune cells better kill cancer cells and is used to treat different types of cancer. Cemiplimab is used to treat certain types of basal cell carcinoma and squamous cell carcinoma of the skin (type of skin cancer) that are locally advanced or have spread to other parts of the body. It may also be used alone or with other drugs to treat adults with non-small cell lung cancer that is locally advanced or has spread to other parts of the body and may have PD-L1 protein but no mutations (changes) in the EGFR, ALK or ROS1 genes. It is also used to treat other types of cancer. Cimepilimab is also calledLibtayo.

Cimepilimab may blockPD-1 and help the immune system kill cancer cells. It is a monoclonal antibody and an immune checkpoint inhibitor. Common adverse reactions currently include fatigue, musculoskeletal pain, rash, diarrhea, and anemia. These adverse reactions sometimes lead to serious or even life-threatening consequences and may continue to occur during or after treatment. Therefore, during the use of cimepilimab, patients need to regularly monitor their physical condition to detect and deal with potential immune-related adverse events in a timely manner.

Cimepril monoclonal antibody is still absent from the domestic market and has not been included in medical insurance, so its price information is still unclear. However, the drug is available overseas in the United States and Europe. The common specification is 350mg/7mL (50mg/mL). The price of each box may range from 40,000 to 100,000 yuan due to exchange rate fluctuations. In addition, there are currently no generic drugs of cimepilimab on the market.

In summary, cimepilimab, as a novel immune checkpoint inhibitor, provides a new treatment option for cancer patients, especially when dealing with refractory and advanced cancers. However, its absence in the country and its high price undoubtedly bring challenges to patient treatment.

Reference materials:https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cemiplimab